

Royalty rate report

LATP26128

Type of agreement

Cross-license agreement

Exclusivity

Exclusive

Year

2009

Licensee

Combinatorx, Inc

Licensor

Pgx Health, Llc

Geography

Global

IP included in license

Know-how, Trade secret,
Patent, R&D

Royalty rate

7.00 %
8.00 %
9.00 %
10.00 %

Royalty base

Net sales

Description

Global exclusive know-how, trade secret, patent and R&D cross-license agreement between Combinatorx (licensee) and Pgx Health (licensor) to develop, make, use, import, sell and market products, which contain compound known as ATL313 in the field of the treatment, prevention and diagnosis of cancer in humans, but specifically excluding the treatment of any ophthalmic disease and the treatment of pain via intrathecal administration.